Scilex Holding (SCLX) Depreciation & Amortization (CF) (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Depreciation & Amortization (CF) of $2.9 million for Q1 2026, up 186.04% year-over-year from $1.0 million in Q1 2025, and up 80.78% quarter-over-quarter from $1.6 million in Q4 2025.
Scilex Holding (SCLX) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Scilex Holding's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 186.04% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $6.5 million (up 61.5% YoY), while the FY2025 annual figure was $4.6 million, up 14.26% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $2.9 million, up from $1.6 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.9 million in Q1 2026, with the low at $944000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $1.0 million (2024), against an average of $1.2 million.
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) declined 3.27% in 2024, then surged 186.04% in 2026.
- Scilex Holding's Depreciation & Amortization (CF) stood at $1.0 million in 2022, then retreated by 0.1% to $1.0 million in 2023, then decreased by 2.9% to $1.0 million in 2024, then jumped by 58.07% to $1.6 million in 2025, then jumped by 80.78% to $2.9 million in 2026.
- Business Quant data shows SCLX's Depreciation & Amortization (CF) at $2.9 million in Q1 2026, $1.6 million in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.96 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.11 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.62 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 2.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |